8 th WHO Vector Control Advisory Group Meeting

Transcription

1 8 th WHO Vector Control Advisory Group Meeting General Progress and Update on VCAG Thomas W. Scott, VCAG Chair 14 May 2018

2 The role of VCAG VCAG serves as an advisory body to WHO on new tools, technologies and approaches for the control of vectors of malaria and other vector-borne diseases. To assist WHO in developing public health policy on new tools, VCAG assesses the public health value of new interventions and provides guidance on developing the evidence base required to inform such assessments by the group. Management of VCAG is a joint responsibility of the WHO Global Malaria Programme (GMP), the Department of Control of Neglected Tropical Diseases (NTD), and the WHO Prequalification Team (PQT) for vector control products.

3 Updates on VCAG activities 1. Current meeting will review 9 products classes, 2 new submissions tools are at stage 3 (epi trials) 3. Staffing update New VCAG Project Manager hired (Ms Anna Bowman) 4. Full integration of WHO PQ-VC into VCAG Secretariat 5. Sustainability exercise and consultation with selected stakeholders on areas for VCAG improvement

4 Generic intervention types Product class Prototype / product Status Insecticide-treated nets that are not Non pyrethroid net Yorkool LN (OP) Initial review pyrethroid-only LLINs Pyrethroid plus non-pyrethroid Interceptor G2 (pyrethroid-chlorfenapyr) VCAG Step 3 insecticide net Pyrethroid plus IGR net Royal Guard LN (pyrethroid-pyriproxifen) VCAG Step 3 Indoor residual spray products Slow-acting insecticide Sylando 240SC (chlorfenapyr) VCAG Step 3 formulation Outdoor residual spray product Perifocal residual spray products Deltamethrin based formulation for extended residual activity on sprayed surfaces Not taken forward by manufacturer Spatial Repellents Indoor passive emanator Transfluthrin passive emanator VCAG Step 3 Attract-and-kill baits Attractive Targeted Sugar Bait Attractive Targeted Sugar Baits VCAG Step 3 (ATSB) Genetic manipulation of vectors for disease control Population reduction self limiting approach Oxitec OX513A Aedes aegypti VCAG Step 3 Population reduction gene-drive CRISP/Cas9 - suppression construct in An VCAG Step 1 approach gambiae Population alteration gene-drive CRISP/Cas9 - anti-p. falciparum construct in An VCAG Step 1 approach stephensi Housing modification Lethal House Lures / Eaves tubes Eave tubes intervention VCAG Step 3 Microbial control of human pathogens in adult vectors Systemic insecticides Vector traps for disease management Sterile insect technique (SIT) combined with microbial infection Fully screened houses (FSH) Pyrethroid-insecticide-treated netting applied for Not taken forward by full house protection manufacturer Wolbachia-based population wmel strain Wolbachia in Aedes aegypti VCAG Step 3 alteration Wolbachia-based population used with SIT below reduction Systemic cattle treatment for Fipronil bolus VCAG Step 3 vector control Rodent bait from vector control Imidacloprid rodent feed product Moved to new product claim Adulticidal Oviposition Traps Vector trap VCAG Step 3 Auto-dissemination devices In2Trap VCAG Step 2 Sterile Insect Technique Sterilized male Ae. aegypti and Ae. albopictus infected with Wolbachia spp. VCAG Step 2

5 VCAG Membership Update Vector ecology, genetics and population biology Thomas W. Scott (Chair VCAG) Heather Ferguson Audrey E. Lenhart (new member 2017) Insecticide resistance and resistance mechanisms Hilary Ranson (new member 2017) Fabrice Chandre (new member 2017) Development and/or evaluation of public health products Eva Bennet (new member 2018) Study design and statistics Steven W. Lindsay Thomas Smith Robert Reiner (new member 2017) NEW CALL FOR VCAG MEMBERSHIP IN 2018! Genetics/Molecular Biology Product development Epidemiology of vector-borne diseases Vector ecology and population biology VCAG will draw on ad-hoc expert groups when needed, for example at this meeting we have an expert on gene drive. Epidemiology of vector-borne diseases Immo Kleinschmidt Salim Abdulla (new member 2017)

6 Logistics Open session: VCAG members invited to speak 1 st followed by observers & stakeholders Closed session interactions with innovators: Applicant presentation (30 min) Closed Discussion (15-20 mins) Recommendation to applicants (10 mins) Reception, Monday 14 May at 17:30, 4 th floor open space all welcome

7 Feedback is welcome We want to hear from you! We have set aside 45 minutes today at the end of the Open Session to hear your feedback Written feedback can be provided to